RBOT Earnings Prediction
The chart below shows how RBOT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RBOT sees a +0.84% change in stock price 10 days leading up to the earnings, and a -7.39% change 10 days following the report. On the earnings day itself, the stock moves by -2.49%. This data can give you a slight idea of what to expect for the next quarter's release.
RBOT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-2.36
-5.36%
-18.62%
No Data Available
RBOT Earnings Analysis
Vicarious Surgical Inc Corporation (RBOT.N) Earnings Conference Call
Positive
Earnings Surprise Report: Vicarious Surgical Inc. beat earnings expectations with a reported EPS of $-2.43, surpassing the expected $-2.69.
System Integration Milestone Achieved: The successful completion of the Version 1.0 System integration was a key milestone, demonstrating functionality and performance in a cadaveric preclinical setting.
Minimally Invasive Surgical System: The Version 1.0 system is designed for minimally invasive surgery with a single small 18-millimeter incision, providing high forces for a broad range of soft tissue indications.
Enhanced Surgical Dexterity: The innovative design of the system allows for 13 degrees of freedom per instrument, enhancing dexterity and visualization for surgeons.
Partnership Expansion for Education: Vicarious Surgical expanded partnerships with leading hospital systems, including LSU Health New Orleans, Temple Health, and University of Illinois Health, which will aid in medical education and training protocols.
Manufacturing and Supply Chain Improvements: The company has made significant strides in establishing a scalable manufacturing foundation, strengthening its supply chain and building redundancies to mitigate disruptions.
Reduced Operating Expenses: Operating expenses for 2024 were down 17% year-over-year, indicating improved financial discipline and cost management.
R&D Expense Reduction: R&D expenses decreased from $47.6 million in 2023 to $40.2 million in 2024, reflecting efficient resource allocation.
Adjusted Net Loss Improvement: The adjusted net loss for 2024 was $63.3 million, an improvement from $76.3 million in 2023, showing progress in financial performance.
Financial Stability Highlight: The company ended 2024 with approximately $49 million in cash, cash equivalents, and short-term investments, underscoring financial stability.
Negative
Adjusted Net Loss Improvement: The company reported an adjusted net loss of $63.3 million for the full year 2024, which is a significant loss despite being an improvement from the previous year's loss of $76.3 million.
Ongoing Financial Loss: The GAAP net loss for the full year was $63.2 million, indicating ongoing financial struggles as the company continues to operate at a loss.
Cash Burn Rate Concerns: The cash burn rate for 2024 was $49 million, which, while slightly better than the original guidance, still indicates a high rate of cash expenditure that could raise concerns about sustainability.
Regulatory Approval Delays: The company expects a de novo submission to be late in 2026, indicating delays in regulatory approval processes that could hinder market entry and revenue generation.
Supply Chain Delays Impacting Trials: There were instances of delays in component delivery and build hurdles with suppliers, which impacted the pace of inventory buildup and could affect the timeline for clinical trials.
Financial Health Concerns: Despite a decrease in operating expenses, the overall financial health remains concerning with a significant net loss and ongoing cash burn, raising questions about future funding and operational viability.
RBOT FAQs
How does RBOT typically perform around its earnings report dates?
Is Vicarious Surgical Inc (RBOT) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
RBOT Earning Call Sentiment
Vicarious Surgical Inc. (NYSE:RBOT) Q4 2024 Earnings Call Transcript
RBOT.N
-14.85%Positive
The earnings call summary presents a mixed picture: improvements in financial metrics and reduced expenses are positive, but supply chain issues and regulatory uncertainties pose risks. The Q&A section reveals management's evasiveness on critical timelines, which may raise investor concerns. The absence of a strong catalyst, such as new partnerships or guidance changes, suggests a neutral sentiment, with stock price likely remaining stable.
